



Advancing Research. Improving Lives.™

April 6, 2020

Dear Patient:

You are receiving this letter because you have participated in and are currently receiving treatment on NRG-GY018, **“A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer.”**

The purpose of this letter is to inform you that out of an abundance of caution (to reduce patient visits to infusion centers) during the COVID-19 pandemic, it has been decided to unblind patients who have completed treatment with paclitaxel and carboplatin and pembrolizumab/placebo and are at the point in the study when they are receiving pembrolizumab/placebo only.

Your doctor will use the group’s standard unblinding process to find out what your blinded treatment assignment is, and your doctor will share this information with you.

If you are receiving placebo maintenance, you will no longer need to be treated. If you are receiving pembrolizumab maintenance, you will continue treatment per the study. All patients will continue to have scans to monitor response to treatment per the study. All patients will complete PRO survey questions per the study.

On behalf of NRG Oncology, the three Group Chairs, and the National Cancer Institute, I want to thank you sincerely for your participation in this important clinical trial and your commitment to discovering better treatments for endometrial cancer and to wish you improved health.

Gratefully,

A handwritten signature in black ink that reads "Robert S. Mannel, MD".

Robert S. Mannel, MD
NRG Oncology
Group Chair